JP2022535816A5 - - Google Patents
Info
- Publication number
- JP2022535816A5 JP2022535816A5 JP2021571671A JP2021571671A JP2022535816A5 JP 2022535816 A5 JP2022535816 A5 JP 2022535816A5 JP 2021571671 A JP2021571671 A JP 2021571671A JP 2021571671 A JP2021571671 A JP 2021571671A JP 2022535816 A5 JP2022535816 A5 JP 2022535816A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cytotoxic agent
- collagen
- linked
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025077691A JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856468P | 2019-06-03 | 2019-06-03 | |
| US62/856,468 | 2019-06-03 | ||
| PCT/US2020/070113 WO2020247974A1 (en) | 2019-06-03 | 2020-06-03 | Methods and compositions for treating cancer with collagen binding drug carriers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077691A Division JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535816A JP2022535816A (ja) | 2022-08-10 |
| JP2022535816A5 true JP2022535816A5 (enExample) | 2023-06-13 |
| JP7680375B2 JP7680375B2 (ja) | 2025-05-20 |
Family
ID=73652058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Active JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
| JP2025077691A Pending JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077691A Pending JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220298225A1 (enExample) |
| EP (1) | EP3976111A4 (enExample) |
| JP (2) | JP7680375B2 (enExample) |
| CN (1) | CN114173822B (enExample) |
| AU (1) | AU2020289485A1 (enExample) |
| BR (1) | BR112021024438A2 (enExample) |
| CA (1) | CA3144535A1 (enExample) |
| MX (1) | MX2021014932A (enExample) |
| WO (1) | WO2020247974A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4671361A1 (en) * | 2023-02-20 | 2025-12-31 | The University of Osaka | CELL DESIGN MOLECULE THAT GIVES CELLS PROTEIN ADHESION PROPERTIES |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| WO2011060242A2 (en) * | 2009-11-13 | 2011-05-19 | Talecris Biotherapeutics, Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| EA201690746A1 (ru) | 2013-10-25 | 2016-12-30 | Фармасайкликс Элэлси | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| DK4074735T3 (da) * | 2014-08-28 | 2025-07-14 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| WO2016054107A1 (en) * | 2014-09-29 | 2016-04-07 | Counterpoint Biomedica Llc | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| SG11202104136YA (en) * | 2018-10-23 | 2021-05-28 | Dragonfly Therapeutics Inc | Heterodimeric fc-fused proteins |
-
2020
- 2020-06-03 JP JP2021571671A patent/JP7680375B2/ja active Active
- 2020-06-03 CA CA3144535A patent/CA3144535A1/en active Pending
- 2020-06-03 WO PCT/US2020/070113 patent/WO2020247974A1/en not_active Ceased
- 2020-06-03 US US17/596,118 patent/US20220298225A1/en active Pending
- 2020-06-03 BR BR112021024438A patent/BR112021024438A2/pt unknown
- 2020-06-03 AU AU2020289485A patent/AU2020289485A1/en active Pending
- 2020-06-03 MX MX2021014932A patent/MX2021014932A/es unknown
- 2020-06-03 CN CN202080055104.6A patent/CN114173822B/zh active Active
- 2020-06-03 EP EP20818032.3A patent/EP3976111A4/en active Pending
-
2025
- 2025-05-08 JP JP2025077691A patent/JP2025121986A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023041829A (ja) | セリンプロテアーゼ分子および療法 | |
| US20210322561A1 (en) | Binding protein drug conjugates comprising anthracycline derivatives | |
| JP2022542886A5 (enExample) | ||
| Curnis et al. | NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors | |
| US5459240A (en) | Peptides which serve as substrates for a phosphokinase and methods for their use to modify antibodies in order to facilitate radioabelling of antibodies with 32 P | |
| JP2020524141A5 (enExample) | ||
| EP3145530B1 (en) | Trail receptor agonists for treatment of fibrotic diseases | |
| JP2024517871A5 (enExample) | ||
| JP2025121986A5 (enExample) | ||
| Frank et al. | Strategies for enhancing antibody delivery to the brain | |
| JP2020509737A5 (enExample) | ||
| McGonigle et al. | Neuropilin-1 drives tumor-specific uptake of chlorotoxin | |
| JP2022535816A5 (enExample) | ||
| CN118873680A (zh) | 用于治疗目的的抗体-脲酶缀合物 | |
| CN107223136B (zh) | 一种将抗体导入细胞内的方法 | |
| WO2016186445A1 (ko) | 암 세포 표적용 펩타이드 및 이의 용도 | |
| US20160022776A1 (en) | Trail receptor agonists for treatment of fibrotic disease | |
| CN1345336A (zh) | 抗体和趋化因子构建物及其在自身免疫疾病治疗中的用途 | |
| CA3177566A1 (en) | Tnf.alpha. immunoconjugate therapy for the treatment of brain tumors | |
| Rathjen et al. | Selective enhancement of the tumour necrotic activity of TNF α with monoclonal antibody | |
| CN111499762A (zh) | 一种包含PDGFRβ特异性亲和体和TNFα的融合蛋白及其用途 | |
| WO2022206881A1 (zh) | 核酸自组装介导的adc药物的构建方法及应用 | |
| Hao et al. | ‘Renovation of old drugs’–can peptide drug conjugates lead the post-ADC era? | |
| Martinez-Torro et al. | Lymphocyte infiltration and antitumoral effect promoted by cytotoxic inflammatory proteins formulated as self-assembling, protein-only nanoparticles | |
| TW201809013A (zh) | 用於藥物遞送之抗體融合蛋白 |